BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 32850332)

  • 1. ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer.
    Hoang VT; Matossian MD; Ucar DA; Elliott S; La J; Wright MK; Burks HE; Perles A; Hossain F; King CT; Browning VE; Bursavich J; Fang F; Del Valle L; Bhatt AB; Cavanaugh JE; Flaherty PT; Anbalagan M; Rowan BG; Bratton MR; Nephew KP; Miele L; Collins-Burow BM; Martin EC; Burow ME
    Front Oncol; 2020; 10():1164. PubMed ID: 32850332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulation.
    Hoang VT; Matossian MD; La J; Hoang K; Ucar DA; Elliott S; Burks HE; Wright TD; Patel S; Bhatt A; Phamduy T; Chrisey D; Buechlein A; Rusch DB; Nephew KP; Anbalagan M; Rowan B; Cavanaugh JE; Flaherty PT; Miele L; Collins-Burow BM; Burow ME
    J Cell Biochem; 2021 Aug; 122(8):835-850. PubMed ID: 33876843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diverse and converging roles of ERK1/2 and ERK5 pathways on mesenchymal to epithelial transition in breast cancer.
    Bhatt AB; Wright TD; Barnes V; Chakrabarty S; Matossian MD; Lexner E; Ucar DA; Miele L; Flaherty PT; Burow ME; Cavanaugh JE
    Transl Oncol; 2021 Jun; 14(6):101046. PubMed ID: 33761370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The extracellular-regulated protein kinase 5 (ERK5) enhances metastatic burden in triple-negative breast cancer through focal adhesion protein kinase (FAK)-mediated regulation of cell adhesion.
    Xu Q; Zhang J; Telfer BA; Zhang H; Ali N; Chen F; Risa B; Pearson AJ; Zhang W; Finegan KG; Ucar A; Giurisato E; Tournier C
    Oncogene; 2021 Jun; 40(23):3929-3941. PubMed ID: 33981002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-143 suppresses epithelial-mesenchymal transition and inhibits tumor growth of breast cancer through down-regulation of ERK5.
    Zhai L; Ma C; Li W; Yang S; Liu Z
    Mol Carcinog; 2016 Dec; 55(12):1990-2000. PubMed ID: 26618772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of ERK5 targeting in triple negative breast cancer.
    Ortiz-Ruiz MJ; Álvarez-Fernández S; Parrott T; Zaknoen S; Burrows FJ; Ocaña A; Pandiella A; Esparís-Ogando A
    Oncotarget; 2014 Nov; 5(22):11308-18. PubMed ID: 25350956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype.
    Zhou C; Nitschke AM; Xiong W; Zhang Q; Tang Y; Bloch M; Elliott S; Zhu Y; Bazzone L; Yu D; Weldon CB; Schiff R; McLachlan JA; Beckman BS; Wiese TE; Nephew KP; Shan B; Burow ME; Wang G
    Breast Cancer Res; 2008; 10(6):R105. PubMed ID: 19087274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.
    Wright TD; Raybuck C; Bhatt A; Monlish D; Chakrabarty S; Wendekier K; Gartland N; Gupta M; Burow ME; Flaherty PT; Cavanaugh JE
    J Cell Biochem; 2020 Feb; 121(2):1156-1168. PubMed ID: 31464004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Mechanisms of Epithelial to Mesenchymal Transition Regulated by ERK5 Signaling.
    Bhatt AB; Patel S; Matossian MD; Ucar DA; Miele L; Burow ME; Flaherty PT; Cavanaugh JE
    Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33572742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells.
    Castro NE; Lange CA
    Breast Cancer Res; 2010; 12(4):R60. PubMed ID: 20687930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrin α9 depletion promotes β-catenin degradation to suppress triple-negative breast cancer tumor growth and metastasis.
    Wang Z; Li Y; Xiao Y; Lin HP; Yang P; Humphries B; Gao T; Yang C
    Int J Cancer; 2019 Nov; 145(10):2767-2780. PubMed ID: 31008533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constitutive activation of MEK5 promotes a mesenchymal and migratory cell phenotype in triple negative breast cancer.
    Matossian MD; Hoang VT; Burks HE; La J; Elliott S; Brock C; Rusch DB; Buechlein A; Nephew KP; Bhatt A; Cavanaugh JE; Flaherty PT; Collins-Burow BM; Burow ME
    Oncoscience; 2021; 8():64-71. PubMed ID: 34026925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulforaphane inhibits epithelial-mesenchymal transition by activating extracellular signal-regulated kinase 5 in lung cancer cells.
    Chen Y; Chen JQ; Ge MM; Zhang Q; Wang XQ; Zhu JY; Xie CF; Li XT; Zhong CY; Han HY
    J Nutr Biochem; 2019 Oct; 72():108219. PubMed ID: 31473507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parathyroid Hormone-Related Protein Inhibition Blocks Triple-Negative Breast Cancer Expansion in Bone Through Epithelial to Mesenchymal Transition Reversal.
    Li J; Camirand A; Zakikhani M; Sellin K; Guo Y; Luan X; Mihalcioiu C; Kremer R
    JBMR Plus; 2022 Jun; 6(6):e10587. PubMed ID: 35720668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A kinome-wide high-content siRNA screen identifies MEK5-ERK5 signaling as critical for breast cancer cell EMT and metastasis.
    Pavan S; Meyer-Schaller N; Diepenbruck M; Kalathur RKR; Saxena M; Christofori G
    Oncogene; 2018 Aug; 37(31):4197-4213. PubMed ID: 29713055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
    Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
    Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
    Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
    Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR is a pivotal player of the E2/ERβ - mediated functional properties, aggressiveness, and stemness in triple-negative breast cancer cells.
    Kyriakopoulou K; Kefali E; Piperigkou Z; Riethmüller C; Greve B; Franchi M; Götte M; Karamanos NK
    FEBS J; 2022 Mar; 289(6):1552-1574. PubMed ID: 34665934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benzidine Induces Epithelial-Mesenchymal Transition of Human Bladder Cancer Cells through Activation of ERK5 Pathway.
    Sun X; Zhang T; Deng Q; Zhou Q; Sun X; Li E; Yu D; Zhong C
    Mol Cells; 2018 Mar; 41(3):188-197. PubMed ID: 29463068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.